Side-by-side comparison of AI visibility scores, market position, and capabilities
Columbus OH precision instruments (NYSE: MTD) Q4 2024 revenue $1.045B (+12%), adjusted EPS $12.41 (+32%); global market leader lab balances and food inspection, pharma/biopharma lab destocking recovery competing with Sartorius.
Mettler-Toledo International Inc. is a Columbus, Ohio-based precision instruments and services company — publicly traded on the New York Stock Exchange (NYSE: MTD) as an S&P 500 Health Care component — manufacturing and marketing the world's most comprehensive range of weighing instruments and precision analytical measurement devices for laboratory, industrial, and food retail applications through approximately 18,000 employees in 40 countries. Mettler-Toledo's product portfolio spans laboratory balances and analytical instruments (used in pharmaceutical R&D and quality control), industrial scales and process analytics (used in chemical, food, and beverage manufacturing), pharmaceutical inspection systems (tablet and capsule inspection lines), food inspection equipment (X-ray and metal detection systems, checkweighers), and retail weighing solutions (supermarket scales). In Q4 2024, Mettler-Toledo reported revenue of $1.045 billion (+12% year-over-year) and adjusted EPS of $12.41 (+32% over the prior-year $9.40) — demonstrating the company's operational leverage as volume returned following the laboratory instruments market's destocking correction. CEO Patrick Kaltenbach has led Mettler-Toledo since 2020, maintaining the company's premium pricing strategy and capital return program (no dividend; all free cash flow directed to share repurchases that have reduced the share count by approximately 50% over the past decade). Mettler-Toledo operates as a category leader in precision weighing with 30%+ global market share and consistently achieves operating margins of 28-30%.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.